Boston Scientific (NYSE: BSX) EVP reports RSU exercise, new grants

Rhea-AI Filing Summary

Boston Scientific EVP & Group President, Cardiology Joseph Michael Fitzgerald reported equity compensation and related share movements. On February 12, 2026, he exercised 3,462 restricted stock units, receiving the same number of Boston Scientific common shares. To cover tax obligations, 1,612 common shares were disposed of at $74.12 per share through share withholding, leaving him with 169,892 common shares held directly. He also received new awards of 18,550 restricted stock units and a stock option for 43,776 shares, each vesting in four equal annual installments beginning on February 12, 2027. Following these transactions, he directly holds 6,924 restricted stock units and 18,550 restricted stock units from the new grant, plus the 43,776-share stock option. An additional 5,234 common shares are reported as held indirectly by his child, and he disclaims beneficial ownership of those shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fitzgerald Joseph Michael

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH MA 01752-1234

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Group Pres, Cardiology

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/12/2026		M		3,462	A	$0.0000(1)	171,504	D
Common Stock	02/12/2026		F		1,612	D	$74.12	169,892	D
Common Stock								5,234(2)	I	By Child

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/12/2026		M			3,462	(3)	02/12/2028(3)	Common Stock	3,462	$0.0000	6,924	D
Restricted Stock Units	(1)	02/12/2026		A		18,550		(4)	02/12/2030(4)	Common Stock	18,550	$0.0000	18,550	D
Stock Option (Right to Buy)	$74.12	02/12/2026		A		43,776		(5)	02/12/2036	Common Stock	43,776	$0.0000	43,776	D

Explanation of Responses:

1. Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

2. The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose.

3. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant.

4. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant.

5. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant.

	/s/ Susan Thompson, Attorney-in-Fact	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did BSX executive Joseph Michael Fitzgerald report?

He reported exercising 3,462 restricted stock units into common shares and a tax-withholding disposition of 1,612 common shares at $74.12. He also received new grants of 18,550 restricted stock units and a stock option for 43,776 shares on February 12, 2026.

How many Boston Scientific (BSX) shares does Joseph Michael Fitzgerald now hold directly?

After the reported transactions, he directly holds 169,892 shares of Boston Scientific common stock. This reflects the RSU exercise and the 1,612-share tax-withholding disposition reported for February 12, 2026, as well as prior holdings already in his direct ownership.

What restricted stock unit grants did the BSX executive receive in this Form 4?

He received 18,550 restricted stock units, each representing a future share of Boston Scientific common stock. These RSUs will be settled in four equal annual installments beginning on February 12, 2027, according to the vesting schedule disclosed in the accompanying footnotes.

What are the terms of the new Boston Scientific (BSX) stock option grant?

The filing shows a grant of a stock option for 43,776 shares of Boston Scientific common stock. This option vests in four equal annual installments beginning on February 12, 2027, and has an expiration date of February 12, 2036, as disclosed in the table.

How many restricted stock units does the BSX executive own after these transactions?

Following the transactions, he beneficially owns 6,924 restricted stock units that remain after exercising 3,462 units, plus 18,550 newly granted restricted stock units. Each restricted stock unit represents a commitment to deliver one share of Boston Scientific common stock in the future.

How are the shares held by Joseph Michael Fitzgerald’s child treated in the BSX Form 4?

The Form 4 reports 5,234 Boston Scientific common shares held indirectly by his child. A footnote states that he disclaims beneficial ownership of these shares, and the report should not be deemed an admission that he is the beneficial owner for any purpose.